Glenmark Pharmaceuticals · NSE: GLENMARK · BSE: 532296
Q1 FY20 results · Apr–Jun 2019
Glenmark Pharmaceuticals reported revenue from operations of ₹2,322.88 crore (up 7.3% from Q1 FY19) and net profit of ₹109.28 crore (down 53.1% from Q1 FY19) for Q1 FY20 (Apr–Jun 2019), on a consolidated basis.
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,322.88 | 2,165.62 | +7.3% | 2,563.47 | −9.4% |
| Other income | 1.67 | 138.22 | −98.8% | 39.06 | −95.7% |
| Total income | 2,324.55 | 2,303.83 | +0.9% | 2,602.53 | −10.7% |
| Profit before tax | 159.84 | 326.70 | −51.1% | 240.31 | −33.5% |
| Net profit for the period | 109.28 | 232.99 | −53.1% | 161.66 | −32.4% |
| EPS, basic (₹) | 3.87 | 8.26 | not comparable | 5.73 | −32.5% |
| Net margin (%) | 4.7 | 10.8 | 6.3 |
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,498.79 | 1,618.41 | −7.4% | 1,587.28 | −5.6% |
| Other income | 68.54 | 173.65 | −60.5% | 168.39 | −59.3% |
| Total income | 1,567.33 | 1,792.06 | −12.5% | 1,755.67 | −10.7% |
| Profit before tax | 276.94 | 495.36 | −44.1% | 358.18 | −22.7% |
| Net profit for the period | 227.84 | 397.39 | −42.7% | 281.29 | −19.0% |
| EPS, basic (₹) | 8.07 | 14.08 | −42.7% | 9.97 | −19.1% |
| Net margin (%) | 15.2 | 24.6 | 17.7 |
Consolidated
- Filed with BSE
- 14 Aug 2019, 16:57 IST
- Board meeting
- 13 Aug 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 Aug 2019, 16:57 IST
- Board meeting
- 13 Aug 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE